{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T13:16:55Z","timestamp":1780406215001,"version":"3.54.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1016\/j.ahj.2008.07.023","type":"journal-article","created":{"date-parts":[[2008,9,7]],"date-time":"2008-09-07T13:17:22Z","timestamp":1220793442000},"page":"826-832","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":237,"title":["Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimbe\/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes"],"prefix":"10.1016","volume":"156","clinical-trial-number":[{"clinical-trial-number":"nct00202878","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Christopher P.","family":"Cannon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Giugliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Blazing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine McCrary","family":"Sisk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Strony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Musliner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn H.","family":"McCabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Veltri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Braunwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Califf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2008.07.023_bib1","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2008.07.023_bib2","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1161\/01.CIR.102.16.1893","article-title":"Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project","volume":"102","author":"Sacks","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2008.07.023_bib3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2008.07.023_bib4","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2008.07.023_bib5","doi-asserted-by":"crossref","first-page":"3Q","DOI":"10.1016\/S0002-9149(98)00769-3","article-title":"Low-density lipoproteins and risk for coronary artery disease","volume":"82","author":"Ballantyne","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2008.07.023_bib6","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/j.jacc.2004.03.046","article-title":"Optimal low-density lipoprotein is 50 to 70 mg\/dl: lower is better and physiologically normal","volume":"43","author":"O'Keefe","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2008.07.023_bib7","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1136\/bmj.322.7289.757","article-title":"Dietary fat intake and prevention of cardiovascular disease: systematic review","volume":"322","author":"Hooper","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.ahj.2008.07.023_bib8","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1161\/CIRCULATIONAHA.104.503995","article-title":"Effect size estimates of lifestyle and dietary changes on all-cause mortality in coronary artery disease patients: a systematic review","volume":"112","author":"Iestra","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2008.07.023_bib9","first-page":"2545","article-title":"Lipid Research Clinics Program","volume":"252","year":"1984","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2008.07.023_bib10","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1161\/01.CIR.0000167560.93138.E7","article-title":"Clinical significance of statin pleiotropic effects: hypotheses versus evidence","volume":"111","author":"Davidson","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2008.07.023_bib11","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.jacc.2005.05.085","article-title":"Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis","volume":"46","author":"Robinson","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2008.07.023_bib12","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1056\/NEJM199010043231404","article-title":"Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)","volume":"323","author":"Buchwald","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2008.07.023_bib13","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jacc.2006.04.070","article-title":"Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy","volume":"48","author":"Cannon","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2008.07.023_bib14","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2008.07.023_bib15","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1161\/01.CIR.0000034044.95911.DC","article-title":"Inhibition of intestinal cholesterol absorption by ezetimibe in humans","volume":"106","author":"Sudhop","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2008.07.023_bib16","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1046\/j.1365-2125.2002.01633.x","article-title":"Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin","volume":"54","author":"Kosoglou","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ahj.2008.07.023_bib17","doi-asserted-by":"crossref","first-page":"33586","DOI":"10.1074\/jbc.M405817200","article-title":"Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis","volume":"279","author":"Davis","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ahj.2008.07.023_bib18","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/S0002-9149(02)02774-1","article-title":"Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia","volume":"90","author":"Gagne","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2008.07.023_bib19","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.amjcard.2004.02.060","article-title":"Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia","volume":"93","author":"Ballantyne","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2008.07.023_bib20","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ahj.2004.11.023","article-title":"Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study","volume":"149","author":"Ballantyne","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2008.07.023_bib21","doi-asserted-by":"crossref","first-page":"587","DOI":"10.4065\/80.5.587","article-title":"A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial","volume":"80","author":"Pearson","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ahj.2008.07.023_bib22","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/j.clinthera.2004.11.016","volume":"26","author":"Bays","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.ahj.2008.07.023_bib23","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.atherosclerosis.2004.10.021","article-title":"Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients","volume":"179","author":"Sager","year":"2005","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ahj.2008.07.023_bib24","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMoa0800742","article-title":"Simvastatin with or without ezetimibe in familial hypercholesterolemia","volume":"358","author":"Kastelein","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2008.07.023_bib25","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.ahj.2005.03.029","volume":"149","author":"Giugliano","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2008.07.023_bib26","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1161\/01.CIR.0000032466.44170.44","article-title":"ACC\/AHA\/NHLBI Clinical Advisory on the Use and Safety of Statins","volume":"106","author":"Pasternak","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2008.07.023_bib27","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","article-title":"Statin-associated myopathy","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA"},{"issue":"Suppl. 9A","key":"10.1016\/j.ahj.2008.07.023_bib28","doi-asserted-by":"crossref","first-page":"30F","DOI":"10.1016\/j.amjcard.2004.07.052","article-title":"Is there value in liver function test and creatine phosphokinase monitoring with statin use?","volume":"94","author":"Sniderman","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2008.07.023_bib29","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial","volume":"292","author":"de Lemos","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2008.07.023_bib30","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-reactive protein levels and outcomes after statin therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2008.07.023_bib31","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.jacc.2005.02.080","article-title":"Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of LDL-C<70 mg\/dl and CRP <2 mg\/L: An analysis of the PROVE-IT TIMI 22 Trial","volume":"45","author":"Ridker","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2008.07.023_bib32","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ahj.2004.06.024","volume":"149","author":"Kastelein","year":"2005","journal-title":"Am Heart J"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000287030800656X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000287030800656X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:37:12Z","timestamp":1757569032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000287030800656X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["S000287030800656X"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2008.07.023","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718277735.793491000","asserted-by":"object"}]},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2008,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimbe\/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2008.07.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}